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Abstract
Background: The insertion of Ventricular Assist Devices is a common strategy for cardiovascular support in
patients with refractory cardiogenic shock. This study sought to determine the impact of ventricular assist devices
on the dynamic relationship between arterial blood pressure and cerebral blood flow velocity.
Methods: A sample of 5 patients supported with a pulsatile ventricular assist device was compared with 5 control
patients. Controls were matched for age, co-morbidities, current diagnosis and cardiac output state, to cases. Beat-
to-beat recordings of mean arterial pressure and cerebral blood flow velocity, using transcranial Doppler were
obtained. Transfer function analysis was performed on the lowpass filtered pressure and flow signals, to assess gain,
phase and coherence of the relationship between mean arterial blood pressure and cerebral blood flow velocity.
These parameters were derived from the very low frequency (0.02-0.07 Hz), low frequency (0.07-0.2 Hz) and high
frequency (0.2-0.35 Hz).
Results: No significant difference was found in gain and phase values between the two groups, but the low
frequency coherence was significantly higher in cases compared with controls (mean ± SD: 0.65 ± 0.16 vs 0.38 ±
0.19, P = 0.04). The two cases with highest coherence (~0.8) also had much higher spectral power in mean arterial
blood pressure.
Conclusions: Pulsatile ventricular assist devices affect the coherence but not the gain or phase of the cerebral
pressure-flow relationship in the low frequency range; thus whether there was any significant disruption of cerebral
autoregulation mechanism was not exactly clear. The augmentation of input pressure fluctuations might contribute
in part to the higher coherence observed.
Background
Ventricular assist devices (VAD) are mechanical pumps
that replace or augment left and/or right ventricular
function in cases of refractory cardiogenic shock.
A number of approaches are currently taken related to
the indications of these devices: VAD can be used as a
bridge to heart transplantation, as a bridge to myocar-
dial recovery leading in some cases to their prolonged
use with meaningful survival and improved quality of
life [1]. Recently VAD have also begun to be used as a
“bridge to destination” that is, they are the final plan for
the patient, being used for many years, until the patient
succumbs.
Fundamental differences regarding cardiac output and
systemic circulation distinguish two main types of VAD:
pulsatile and continuous-flow VAD. The main advan-
tages of continuous-flow VAD being the self-contained
nature, not requiring a pneumatic driver, longevity, lack
of bearing contacting with blood and absence of artifi-
cial valves with theoretically smaller thrombogenic sur-
face [2]. However, the effects of non-pulsatile perfusion
on end-organ function remain controversial [3-5]. Pulsa-
tile circulation and its effects on systemic vascular resis-
tances have been related to the improvement of
microcirculation and endothelial integrity [6,7]; reduc-
tion in splanchnic perfusion and reduction of intestinal
edema [8]; improvement of the cerebral haemodynamics
and cerebrospinal fluid drainage [2] and the mainte-
nance of neuro-endocrine cascades, specifically within
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[5].
Despite the use of pulsatile VADs, non-homogeneous
output is often generated as pulsatile VADs eject once
the pre-established filling volume (stroke volume) has
been reached. Therefore, the VAD ejection rate varies
depending on preload and systemic resistance. Fre-
quently there is a variable degree of persistent native
cardiac contractibility, leading to asynchrony, and irre-
gularities in arterial blood pressure waveform (Figure 1).
In such situations of circulatory irregularity, end-organ
perfusion such as cerebral blood flow may require an
intact autoregulation to ensure stable microcirculation.
Cerebral autoregulation is the mechanism by which
cerebral blood flow (CBF) is maintained despite changes
in cerebral perfusion pressure (CPP). Cerebral autoregu-
lation mediates states of hyperemia and ischemia to
avoid vasogenic edema or infarction respectively [9].
Impaired autoregulation has been regarded as a risk fac-
tor associated with adverse neurological outcome after
cardiac surgery [10,11]. As a dynamic phenomenon,
cerebral autoregulation may respond to spontaneous
and induced changes in arterial blood pressure (BP)
such as those occurring with pulsatile VADs [12,13].
Cerebral autoregulation has been extensively studied
using transcranial Doppler (TCD) which measures cere-
bral blood flow velocities (CBFV) as a surrogate of CBF
[14,15] using a variety of methods [16]. From all
described methods, transfer function analysis (TFA)
enables the analysis of phase shift, gain and coherence
between two signals (arterial BP as input and CBFV as
output) at a range of frequencies, and has the advantage
of being applicable for continuous and non-invasive
testing of cerebral autoregulation at the bedside.
Rider and coworkers assessed cerebral autoregulation
in patients supported with non-pulsatile VADs, by
exposing them to dynamic maneuvers such as head-up
tilting and measuring the change in CBFV. They found
that cerebral autoregulation was impaired, suggesting
that circulatory pulsatility is crucial for the maintenance
of cerebral autoregulation [17]. However, their study
occurred during the acute phase of the disease, after the
Figure 1 Real time, beat-to-beat traces of arterial blood pressure (BP) and cerebral blood flow velocity (CBFV) with a ventricular assist
device (VAD). Upper channel: arterial BP waveform in a patient supported with a VAD, showing irregular fluctuations; middle channel: CBFV
(insonated at the level of middle cerebral artery) with fluctuations transmitted from arterial BP; lower channel: electrocardiogram (ECG).
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cardial “modeling” [18] could have occurred. Some
authors have demonstrated that even with the use of
non-pulsatile VAD, if a recovery time is allowed, CBF
shows recovery of its pulsatility [2], attributing this find-
ing to overall myocardial recovery and specifically right
ventricular recovery. Whilst previous study examined
the effects of non-pulsatile VAD on the regulation of
steady state CBF, this study is the first to investigate the
effects of pulsatile VAD, which generates irregular pres-
sure waveform patterns, on the dynamic cerebral pres-
sure-flow relationship by applying the cross-spectral
TFA technique.
Methods
Institutional Ethics Committee approval for the perfor-
m a n c eo ft h es t u d yw a sg r a n t e d .A l lp a t i e n t so rt h e i r
next of kin gave informed consent prior to enrolment in
the study.
A convenience sample of five patients supported with
a pulsatile Thoratec VAD (Thoratec corporation, Plea-
senton, CA, US) was compared with five control
patients, matched for age, comorbidities, current diagno-
sis and cardiac output state (Table 1). All cases were
supported with a left ventricular pulsatile VAD and ino-
tropic drugs for an average of 7 days. All patients were
in their acute phase of their disease. Control subjects
were in a low output state requiring inotropic or vaso-
pressor support but without the support of VAD.
Although their mean arterial blood pressure (MAP) was
similar to the VAD cases, their native left ventricular
ejection fraction (LV EF) was better. All patients in the
control group survived, whereas 2 of the VAD cases
died (Table 2).
We recorded at least 5 minutes of data under resting
conditions in all subjects. Simultaneous beat-to-beat
recordings of BP and cerebral blood flow velocity (CBFV)
waveforms were sampled using a data acquisition unit
(ADInstruments, Australia). The BP waveform was
acquired from an intra-arterial catheter; CBFV of middle
cerebral artery (MCA) was measured using a transcranial
Doppler device with a 2 MHz probe and a power of 100
mW/cm
2 (DWL, Germany). CBFV of middle cerebral
arteries (MCAs) were measured using TCD following
referenced criteria at the temporal acoustic window [15].
Both MCAs were insonated and the side with best acoustic
characteristics chosen for study. Intra-patient variability
was minimized by using only one investigator formally
trained in TCD [16]. Stability of the insonated vessel dia-
meter was assumed by maintaining a stable partial pressure
of arterial carbon dioxide (pCO2) during measurements.
Therapeutic and clinical variables were recorded at the
moment of data acquisition. This study was merely
observational and did not interfere with the treating
physician’s management plan.
Spectral Analysis
For the assessment of cerebral autoregulation, this study
used TFA based on frequency domain cross-spectral
analysis. TFA assesses the relationship between two sig-
nals in the frequency domain and yields three interpre-
table parameters (i.e. gain, phase, and coherence). Gain
is the indicator of the magnitude with which the change
of output signal (i.e. CBFV) is caused by the change of
input signal (i.e. BP). In the context of cerebral autore-
gulation analysis, a small gain indicates that cerebral
blood flow does not change significantly when blood
pressure changes, indicating that the cerebral autoregu-
latory mechanisms are intact. Phase shift relates to the
temporal lag between BP and CBFV at each frequency.
Zero phase lag signifies synchronous fluctuations, whilst
positive phase suggests CBFV leading BP, and negative
phase suggests BP leading CBFV.
The gain and phase metrics, however, need to be
interpreted in the context of the cross-spectral coher-
ence, which is an estimation of the linear correlation
between the input and output signals at particular fre-
quencies. Coherence varies between 0 and 1; where 0
indicates no linear relationship and 1 indicates perfect
linear relationship. It has been suggested that an
increase in coherence may be indicative of a blunted
cerebral autoregulation [21]. A low coherence, however,
can be interpreted as presence of external noise/input,
or nonlinear/lack of relationship between input and
output.
In this study, spectral analysis was performed on
5 min artifact-free segments of continuous CBFV and
BP signals. Signals were downsampled to 1 Hz after
appropriate anti-aliasing lowpass filtering, with any slow
trend removed by cubic spline detrending. The fre-
quency spectra and transfer function were obtained
using the Welch method [21]. This involved subdividing
Table 1 Demographics and patients’ characteristics
VAD Age (years) Pathology comorbidities day of admission
VAD1 52 MI none day 2
VAD2 43 MI hypertension day 29
VAD3 25 OHCA + MI none day 25
VAD4 35 OHCA hypertension day 7
VAD5 63 OHCA hypertension day 25
Control
C1 64 MI none day 5
C2 65 MI hypertension day 4
C3 69 OHCA + MI hypertension day 3
C4 55 OHCA hypertension day 3
C5 50 OHCA hypertension day 2
MI: Myocardial infarct; OHCA: Out of hospital cardiac arrest.
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ing in 7 segments), multiplying each segment with a
Hanning window, then performing a Fast Fourier Trans-
form (FFT), and finally averaging to give the spectra.
Defining the autospectra of BP and CBFV as Sxx(f)a n d
Syy(f)( w i t hf denoting frequency), the cross-spectrum of
BP and CBFV, Sxy(f), was computed as the product of
Sxx*(f) and Syy(f)( asterisk denotes the complex conjugate).
The transfer function from BP to CBFV was computed
as H(f)=Sxy(f)/Sxx(f), and the gain magnitude and phase
angle of the transfer function was obtained accordingly.
The magnitude-squared coherence function was com-
puted as g
2(f)=| Sxy(f)|
2/Sxx(f)Syy(f), for detecting linear
correlation between the spectral components in the two
signals. Coherence ranged from 0 (lack of linear correla-
tion)t o1( perfect linear relationship).
The spectral powers of BP and CBFV and the mean
values of the transfer function gain, phase and coher-
ence were calculated in the very low frequency (VLF,
0.02-0.07 Hz), low frequency (LF, 0.07-0.20 Hz) and
high frequency (HF, 0.20-0.35 Hz) ranges as previously
defined [22]. Unpaired Student’s t-test was performed to
compare the variables between the VAD and the control
groups. P < 0.05 was considered statistically significant.
Results
The patient characteristics are presented in table 1 and 2.
No significant difference in MAP, pCO2 and LVEF was
found between the VAD and the control groups. The
levels of pCO2 were maintained within normal ranges
and stable throughout the study, thus the effect of CO2
on cerebral vessel was minimised. LVEF was generally
lower for the VAD cases, whichwas expected as these
were patients with baseline refractory cardiogenic shock
who required a VAD for life support. However the differ-
ence did not reached statistical significance.
The results from spectral and cross-spectral transfer
function analysis of MAP and CBFV were presented in
table 3 and 4. Display of gain, phase and coherence for
a representative case and control are shown in figures 2
and 3 respectively. No significant difference was found
between the VAD and the control groups, apart from a
significantly higher LF coherence between MAP and
CBFV in the VAD cases (P = 0.04).
Discussion
In this study, the cross-spectral transfer function analy-
sis technique was applied to study the dynamic relation-
ship between systemic BP and CBFV in patients using
pulsatile VAD. The rationale was to describe any poten-
tial alteration of cerebral autoregulation function asso-
ciated with the use of VAD, as the long term use of
VAD may lead to impaired cerebral autoregulation and
worse neurological outcomes.
The key finding of the study was the higher coherence
between MAP and CBFV in the VAD patients compared
with the controls, at the LF range. A low coherence
between MAP and CBFV (<0.5)indicates a lack of linear
relationship between pressure and flow at the particular
frequency range, and can be attributed to the presence
of an intact cerebral autoregulation that introduces non-
linearity relationship [21,22]. It has been suggested that
the complex nonlinear behavior of the cerebral vascula-
ture might be responsible for the low coherences at the
VLF and LF ranges [24-26]. The augmented LF coher-
ence in the VAD patients, on the other hand, might
suggest a lower degree of cerebral autoregulation, possi-
bly due to disruption of autoregulatory mechanisms by
Table 2 Therapy and clinical variables
VAD Support therapy MAP (mmHg) CBFV (cm/s) PCO2 (mmHg) LV EF (%) Outcome
VAD1 VAD 82 38 36 35 Survived
VAD2 VAD 96 47 40 30 Survived
VAD3 VAD + DPM + NA 60 101 42 20 Intrahospital death
VAD4 VAD 74 45 40 20 Survived
VAD5 VAD + DPM 70 39 32 15 Intrahospital death
Mean ± SD 76 ± 14 54 ± 26 38 ± 4 24 ± 8
Control
C1 DPM 79 36 42 40 Survived
C2 DPM 90 43 35 25 Survived
C3 DPM + DBT 70 53 48 30 Survived
C4 DPM + NA 75 39 41 30 Survived
C5 DPM 80 42 37 40 Survived
Mean ± SD 79 ± 7 43 ± 6 41 ± 5 33 ± 7
P 0.74 0.36 0.39 0.09
VAD: Ventricular Assist Device; MAP: Mean Arterial Pressure; CBFV: cerebral blood flow velocity (mean values are given); LV EF: Left Ventricular Ejection Fraction;
NA: Noradrenaline; DPM: Dopamine; DBT: Dobutamine.
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this interpretation was that, although no significant dif-
ference in the MAP power was observed between the
two groups, the two VAD patients with the highest
coherence (~0.8) also had much higher spectral power
in MAP than the rest of the group. It has been sug-
gested that an increased input pressure change might
lead to an increase in coherence, via an improved
“signal-to-noise” ratio [27]. This effect might contribute
in part to the higher coherence in the VAD group.
The lack of differences in TFA gain and phase between
the VAD and the control group also raised questions
whether there was significant disruption of cerebral auto-
regulation by the use of pulsatile VAD. Alterations in
Table 3 Power spectrum analysis of mean arterial pressure (MAP) and mean cerebral blood flow velocity (CBFV) in
ventricular assist device (VAD) cases and controls
VAD VLF LF HF
pMAP pCBFV pMAP pCBFV pMAP pCBFV
VAD1 0.80 2.77 0.28 0.48 0.94 0.47
VAD2 2.34 7.94 2.41 3.77 0.32 1.46
VAD3 1.06 3.22 0.20 0.94 8.88 3.72
VAD4 3.26 6.55 4.42 3.67 2.15 1.79
VAD5 2.97 2.61 0.49 1.14 5.44 2.24
Mean ± SD 2.09 ± 1.11 4.62 ± 2.46 1.56 ± 1.84 2.00 ± 1.59 3.55 ± 3.58 1.94 ± 1.19
Control VLF LF HF
pMAP pCBFV pMAP pCBFV pMAP pCBFV
C1 0.47 1.12 1.55 0.80 3.80 0.56
C2 1.52 4.92 0.08 0.61 2.44 1.42
C3 2.43 6.93 0.10 0.43 2.55 1.69
C4 0.95 2.72 0.23 0.65 0.17 0.25
C5 0.24 1.20 0.70 1.42 1.98 3.23
Mean ± SD 1.12 ± 0.88 3.38 ± 2.51 0.53 ± 0.62 0.78 ± 0.38 2.19 ± 1.31 1.43 ± 1.17
P 0.17 0.45 0.27 0.13 0.45 0.52
VLF, very low frequency (0.02-0.07 Hz); LF, low frequency (0.07-0.2 Hz); HF, high frequency (0.2-0.35 Hz). pMAP (in mmHg
2) and pCBFV (in (cm/s)
2) are spectral
powers of MAP and mean CBFV respectively.
*P < 0.05 from t-test between VAD and Control.
Table 4 Transfer function analysis (TFA) of mean arterial pressure (MAP) and mean cerebral blood flow velocity (CBFV)
in ventricular assist device (VAD) cases and controls
VAD VLF LF HF
Coh Gain Phase Coh Gain Phase Coh Gain Phase
VAD1 0.67 1.35 1.00 0.65 1.20 -0.38 0.67 0.75 0.51
VAD2 0.76 1.82 0.98 0.79 1.25 -0.08 0.68 1.96 0.30
VAD3 0.20 0.95 0.32 0.45 1.52 0.27 0.54 1.13 0.21
VAD4 0.44 0.89 0.90 0.82 0.83 0.51 0.74 0.79 0.16
VAD5 0.45 0.63 1.04 0.56 1.18 0.72 0.77 0.72 0.00
Mean ± SD 0.50 ± 0.22 1.13 ± 0.47 0.85 ± 0.30 0.65 ± 0.16 1.20 ± 0.25 0.21 ± 0.44 0.68 ± 0.09 1.07 ± 0.52 0.24 ± 0.19
Control VLF LF HF
Coh Gain Phase Coh Gain Phase Coh Gain Phase
C1 0.13 0.55 0.73 0.65 0.65 0.62 0.74 0.36 -0.09
C2 0.61 1.43 0.63 0.21 1.71 -0.24 0.32 2.29 0.27
C3 0.72 1.33 0.33 0.30 1.89 0.07 0.34 2.24 -0.15
C4 0.46 1.12 -0.27 0.25 1.07 -0.40 0.28 1.02 -0.18
C5 0.25 1.15 -1.71 0.51 1.18 0.76 0.91 1.28 0.21
Mean ± SD 0.43 ± 0.25 1.12 ± 0.34 -0.06 ± 1.00 0.38 ± 0.19 1.30 ± 0.50 0.16 ± 0.51 0.52 ± 0.29 1.44 ± 0.83 0.01 ± 0.21
P 0.65 0.96 0.089 0.039* 0.69 0.88 0.26 0.42 0.11
VLF, very low frequency (0.02-0.07 Hz); LF, low frequency (0.07-0.2 Hz); HF, high frequency (0.2-0.35 Hz). Coh, gain (in cm/s/mmHg) and phase (in rad) are the
transfer function coherence, gain and phase from MAP to mean CBFV.
*P < 0.05 from t-test between VAD and Control.
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tions (such as stroke and autonomic failure [28,29]) are
typically associated with changes in gain and/or phase,
which were not observed in the current study. Never-
thelss, it appeared that the highpass filtering property of
the cerebral circulation, characterised by smaller gain at
the lower frequencies (VLF) and an increase in gain
towards the higher frequencies (HF) [21,27], was more
apparent in the control group compared with the VAD
group. It would therefore still be possible that gain prop-
erties of cerebral autoregulation might have changed in
the VAD patients, although the interpretation of the gain
parameter would have been limited somewhat by the low
coherences in the control patients.
Methodological considerations and limitations
In this study, direct assessment of CBF was not feasible
as the use of non-imaging TCD does not facilitate the
measurement of the cerebral vessel cross-sectional area.
Instead, there is a global consensus supporting the use
of CBFV as a surrogate for CBF, provided the vessel
diameter remains stable during the study [30]. Among
all factors intervening in changes of vessel diameter and
therefore determining CBF [23], pCO2 is directly related
with vessel diameter and was maintained stable and
within normal values, during patient recruitment.
For TCD recordings, only the MCA with better acous-
tic properties was recorded and analyzed. Although spa-
tial heterogeneity of cerebral perfusion as well as
interhemispheric differences has been described [30];
the endpoint in this study was to ensure the best tran-
scranial Doppler recordings in order to minimize the
signal-to-noise ratio and increase data reliability [30].
No significant change in gain and phase was found
between the two groups in this study, but the small
population recruited could have contributed to the lack
of statistical significance, thus further studies with larger
sample size would be desirable.
Conclusion
The use of pulsatile VAD affected the coherence but not
the gain or phase of the cerebral pressure-flow relationship
Figure 2 Transfer function analysis (TFA) of mean arterial pressure (MAP) and cerebral blood flow velocity (CBFV) in a patient with
ventricular assist device (VAD). The gain, phase and coherence spectra of a representative case with VAD were shown.
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significant disruption of cerebral autoregulation mechan-
ism was not clear. The augmentation of input pressure
fluctuations might contribute in part to the higher coher-
ence observed. Given the absence of all conditions that
define autoregulation, these results should be regarded as
preliminary data, and further studies, employing bigger
samples, are warranted.
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